Nevertheless, given the previously noted non-differential KRAS expression among the different stages of dysplasia, the prevalence of KRAS mutations throughout different IPMN subtypes, and the insignificance to the survival outcomes in patients with IPMN, it can be doubted that knowing the KRAS status would be of significant prognostic and clinical value [35,38,39]. The gene discussed is KRAS; the disease is pancreatic intraductal papillary-mucinous neoplasm.